KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Operating Expenses (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Operating Expenses for 8 consecutive years, with $112.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 13.54% to $112.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $547.9 million through Dec 2025, down 17.16% year-over-year, with the annual reading at $547.9 million for FY2025, 17.16% down from the prior year.
  • Operating Expenses hit $112.0 million in Q4 2025 for Vir Biotechnology, down from $173.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $241.0 million in Q4 2021 to a low of $112.0 million in Q4 2025.
  • Historically, Operating Expenses has averaged $171.9 million across 5 years, with a median of $167.7 million in 2024.
  • Biggest five-year swings in Operating Expenses: skyrocketed 118.81% in 2021 and later tumbled 33.86% in 2024.
  • Year by year, Operating Expenses stood at $241.0 million in 2021, then fell by 17.05% to $199.9 million in 2022, then decreased by 22.06% to $155.8 million in 2023, then decreased by 16.87% to $129.5 million in 2024, then fell by 13.54% to $112.0 million in 2025.
  • Business Quant data shows Operating Expenses for VIR at $112.0 million in Q4 2025, $173.7 million in Q3 2025, and $119.6 million in Q2 2025.